Human papillomavirus and survival of patients with oropharyngeal cancer; Cetuximab-induced anaphylaxis and IgE specific for galactose-α-1, 3-galactose; PD-1 blockade with cemiplimab in advanced cutaneous squamous-cell carcinoma; Chromosomal instability drives metastasis through a cytosolic DNA response; Molecular classification of head and neck squamous cell carcinomas using patterns of gene expression; Increased epidermal growth factor receptor gene copy number is associated with poor prognosis in head and neck squamous cell carcinomas; Tobacco smoking and increased risk of death and progression for patients with p16-positive and p16-negative oropharyngeal cancer; Human papillomavirus in head and neck cancer: its role in pathogenesis and clinical implications; Detection of somatic mutations and HPV in the saliva and plasma of patients with head and neck squamous cell carcinomas; Randomized phase III trial to test accelerated versus standard fractionation in combination with concurrent cisplatin for head and neck carcinomas in the Radiation Therapy …; E1308: phase II trial of induction chemotherapy followed by reduced-dose radiation and weekly cetuximab in patients with HPV-associated resectable squamous cell carcinoma of …; p16 protein expression and human papillomavirus status as prognostic biomarkers of nonoropharyngeal head and neck squamous cell carcinoma; Gene expression differences associated with human papillomavirus status in head and neck squamous cell carcinoma; Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1–2 trials; Antitumor activity of nivolumab in recurrent and metastatic nasopharyngeal carcinoma: an international, multicenter study of the mayo clinic phase 2 consortium (NCI-9742); Molecular portraits and the family tree of cancer; lncRNA MIR100HG-derived miR-100 and miR-125b mediate cetuximab resistance via Wnt/β-catenin signaling; Gene expression profiles identify epithelial-to-mesenchymal transition and activation of nuclear factor-κB signaling as characteristics of a high-risk head and neck squamous …; Emerging biomarkers in head and neck cancer in the era of genomics; Managing premedications and the risk for reactions to infusional monoclonal antibody therapy
